Ironwood Pharmaceuticals (IRWD) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Ironwood Pharmaceuticals (IRWD) has outperformed Syndax Pharmaceuticals (SNDX) over the past year, gaining 48.7% versus a loss of 50.0%. Over five years, SNDX leads with a -47.1% price change compared with -57.9% for IRWD. Syndax Pharmaceuticals is the larger company by market cap ($785.0 million vs $778.1 million), about 1.0 times the size.
Ironwood Pharmaceuticals converts more of its revenue into profit, with a net margin of 8.1% versus -165.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IRWD | SNDX |
|---|---|---|
| Share price | $4.70 | $8.72 |
| Market cap | $778.09M | $785.05M |
| 1-day change | -0.21% | -4.49% |
| YTD return | +39.47% | -58.50% |
| 1-year return | +48.73% | -50.00% |
| 5-year return | -57.89% | -47.09% |
| P/E ratio (TTM) | 5.22 | — |
| Forward P/E | 3.00 | — |
| EPS (TTM) | $0.90 | $-2.37 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $296.15M | $172.35M |
| Revenue growth (YoY) | -15.72% | +627.84% |
| Net income (latest FY) | $24.02M | $-285.42M |
| Operating margin | 33.26% | -158.45% |
| Net margin | 8.11% | -165.60% |
| 52-week high | $5.78 | $25.59 |
| 52-week low | $2.95 | $8.41 |
| Distance from 52-week high | -18.69% | -65.92% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +31.49% | +306.54% |
| Average volume | 2.15M | 2.63M |
| Shares outstanding | 165.55M | 90.03M |
| Employees | 100 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRWD has outperformed SNDX by 98.7 percentage points over the past year.
- Ironwood Pharmaceuticals is more profitable, keeping 8.1 cents of every revenue dollar as net income versus -165.6 cents for Syndax Pharmaceuticals.
- Syndax Pharmaceuticals grew revenue faster in its latest fiscal year (+627.84% vs -15.72%).
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
IRWD vs SNDX FAQ
Which is bigger, Ironwood Pharmaceuticals or Syndax Pharmaceuticals?
Syndax Pharmaceuticals (SNDX) is larger, with a market capitalization of $785.05M compared with $778.09M for Ironwood Pharmaceuticals (IRWD).
Which stock has performed better over the past year, IRWD or SNDX?
IRWD returned +48.73% over the past 12 months, compared with -50.00% for SNDX (price return, excluding dividends). Past performance does not predict future results.
Are Ironwood Pharmaceuticals and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.